{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:15:02Z","timestamp":1772165702589,"version":"3.50.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,11,4]],"date-time":"2019-11-04T00:00:00Z","timestamp":1572825600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,11,4]],"date-time":"2019-11-04T00:00:00Z","timestamp":1572825600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"the Natural Science Foundation of Beijing Municipality","award":["7172071"],"award-info":[{"award-number":["7172071"]}]},{"DOI":"10.13039\/501100005153","name":"the China National Funds for Distinguished Young Scientists","doi-asserted-by":"crossref","award":["81500157"],"award-info":[{"award-number":["81500157"]}],"id":[{"id":"10.13039\/501100005153","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Secondary central nervous system lymphoma (SCNSL) is defined as secondary central nervous system (CNS) involvement in patients with systemic lymphoma. It is considered a profoundly adverse complication with inferior clinical outcome. Parenchymal involvement in the CNS in aggressive B-cell lymphoma is not frequently seen and remains a diagnostic dilemma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In our study, we retrospectively analyzed the clinical and magnetic resonance imaging (MRI) features of 26 parenchymal SCNSL patients. In addition, we compared MRI features of SCNSL and primary CNS lymphoma (PCNSL) patients after 1:1 propensity score matching. Also we presented two SCNSL cases with atypical MRI appearance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among SCNSL patients, the median CNS relapse time was 3\u2009months, and multiple lesions were found in 76.9% of the cases. In PCNSL, this percentage was 42.3% (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.011). None of the SCNSL patients and 23.1% of the PCNSL patients had solitary infratentorial lesions (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.003).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The majority of parenchymal involvement occurred within the first year of systemic lymphoma, in which mostly cases presenting with multiple and supratentorial locations, unlike what was found in PCNSL.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12883-019-1511-3","type":"journal-article","created":{"date-parts":[[2019,11,4]],"date-time":"2019-11-04T11:02:57Z","timestamp":1572865377000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Parenchymal central nervous system involvement in aggressive B-cell lymphoma: retrospective analysis of clinical and MRI features in a Chinese population"],"prefix":"10.1186","volume":"19","author":[{"given":"Yuchen","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaming","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuefei","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xueyan","family":"Bai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Qian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qu","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruixian","family":"Xing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuedan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiayuan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nan","family":"Ji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shengjun","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanbo","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,11,4]]},"reference":[{"issue":"3","key":"1511_CR1","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1001\/jamaneurol.2013.606","volume":"70","author":"BJ Scott","year":"2013","unstructured":"Scott BJ, Douglas VC, Tihan T, Rubenstein JL, Josephson SA. A systematic approach to the diagnosis of suspected central nervous system lymphoma. JAMA neurology. 2013;70(3):311\u20139. \n                    https:\/\/doi.org\/10.1001\/jamaneurol.2013.606\n                    \n                  .","journal-title":"JAMA neurology"},{"issue":"3","key":"1511_CR2","doi-asserted-by":"publisher","first-page":"509","DOI":"10.3109\/10428194.2013.811239","volume":"55","author":"J Zhang","year":"2014","unstructured":"Zhang J, Chen B, Xu X. Impact of rituximab on incidence of and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: a systematic review and meta-analysis. Leukemia & lymphoma. 2014;55(3):509\u201314. \n                    https:\/\/doi.org\/10.3109\/10428194.2013.811239\n                    \n                  .","journal-title":"Leukemia & lymphoma."},{"issue":"10","key":"1511_CR3","doi-asserted-by":"publisher","first-page":"2228","DOI":"10.3109\/10428194.2013.869326","volume":"55","author":"CD Fletcher","year":"2014","unstructured":"Fletcher CD, Kahl BS. Central nervous system involvement in diffuse large B-cell lymphoma: an analysis of risks and prevention strategies in the post-rituximab era. Leukemia & lymphoma. 2014;55(10):2228\u201340. \n                    https:\/\/doi.org\/10.3109\/10428194.2013.869326\n                    \n                  .","journal-title":"Leukemia & lymphoma."},{"issue":"6","key":"1511_CR4","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1023\/A:1008394827806","volume":"11","author":"C. Haioun","year":"2000","unstructured":"Haioun C, Besson C, Lepage E, Thieblemont C, Simon D, Rose C, et al. Incidence and risk factors of central nervous system relapse in histologically aggressive non-Hodgkin's lymphoma uniformly treated and receiving intrathecal central nervous system prophylaxis: a GELA study on 974 patients. Groupe d'Etudes des Lymphomes de l'Adulte. Annals of oncology : official journal of the European Society for Medical Oncology. 2000;11 6:685\u201390.","journal-title":"Annals of Oncology"},{"issue":"2","key":"1511_CR5","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1532\/ijh97.06091","volume":"84","author":"N Tomita","year":"2006","unstructured":"Tomita N, Kodama F, Kanamori H, Motomura S, Ishigatsubo Y. Secondary central nervous system lymphoma. Int J Hematol. 2006;84(2):128\u201335. \n                    https:\/\/doi.org\/10.1532\/ijh97.06091\n                    \n                  .","journal-title":"Int J Hematol"},{"issue":"3\u20134","key":"1511_CR6","doi-asserted-by":"publisher","first-page":"335","DOI":"10.3109\/10428190009087024","volume":"38","author":"N Tomita","year":"2000","unstructured":"Tomita N, Kodama F, Sakai R, Koharasawa H, Hattori M, Taguchi J, et al. Predictive factors for central nervous system involvement in non-Hodgkin's lymphoma: significance of very high serum LDH concentrations. Leukemia & lymphoma. 2000;38(3\u20134):335\u201343. \n                    https:\/\/doi.org\/10.3109\/10428190009087024\n                    \n                  .","journal-title":"Leukemia & lymphoma"},{"issue":"2","key":"1511_CR7","doi-asserted-by":"publisher","first-page":"235","DOI":"10.3324\/haematol.2016.149120","volume":"102","author":"Francisco-Javier Pe\u00f1alver","year":"2016","unstructured":"Pe\u00f1alver FJ, Sancho JM, De lFA, Olave MT, Martin A, Panizo C, et al. Guidelines for diagnosis, prevention and management of central nervous system involvement in diffuse large B-cell lymphoma patients by the Spanish Lymphoma Group (GELTAMO). Haematologica. 2017;102 2:235.","journal-title":"Haematologica"},{"issue":"22","key":"1511_CR8","doi-asserted-by":"publisher","first-page":"5034","DOI":"10.1200\/jco.2005.13.524","volume":"23","author":"LE Abrey","year":"2005","unstructured":"Abrey LE, Batchelor TT, Ferreri AJ, Gospodarowicz M, Pulczynski EJ, Zucca E, et al. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005;23(22):5034\u201343. \n                    https:\/\/doi.org\/10.1200\/jco.2005.13.524\n                    \n                  .","journal-title":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology"},{"issue":"6","key":"1511_CR9","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.26420\/annhematoloncol.2018.1211","volume":"5","author":"R MacCann","year":"2018","unstructured":"MacCann R, Gleeson JP, Aird JJ, Beausang A, Breathnach O, Morris PG, et al. An unusual presentation of a low grade follicular lymphoma masquerading as a meningioma. Ann Hematol Oncol. 2018;5(6):1211.","journal-title":"Ann Hematol Oncol"},{"issue":"6","key":"1511_CR10","first-page":"867","volume":"29","author":"A Burgetova","year":"2008","unstructured":"Burgetova A, Seidl Z, Vaneckova M, Jakoubkova M. Concurrent occurrence of multiple sclerosis and primary CNS lymphoma: a case report. Neuro endocrinology letters. 2008;29(6):867\u201370.","journal-title":"Neuro endocrinology letters"},{"issue":"5","key":"1511_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3171\/foc.2006.21.5.4","volume":"21","author":"Matthew A. Hunt","year":"2006","unstructured":"Hunt MA, Jahnke K, Murillo TP, Neuwelt EA. Distinguishing primary central nervous system lymphoma from other central nervous system diseases: a neurosurgical perspective on diagnostic dilemmas and approaches. Neurosurgical focus. 2006;21 5:E3.","journal-title":"Neurosurgical Focus"},{"key":"1511_CR12","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ejca.2018.01.073","volume":"93","author":"Tarec Christoffer El-Galaly","year":"2018","unstructured":"El-Galaly TC, Cheah CY, Bendtsen MD, Nowakowski GS, Kansara R, Savage KJ, et al. Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma. European journal of cancer (Oxford, England : 1990). 2018;93:57\u201368; doi: \n                    https:\/\/doi.org\/10.1016\/j.ejca.2018.01.073\n                    \n                  .","journal-title":"European Journal of Cancer"},{"issue":"25","key":"1511_CR13","doi-asserted-by":"publisher","first-page":"3061","DOI":"10.1200\/JCO.2012.46.9957","volume":"31","author":"James L. Rubenstein","year":"2013","unstructured":"Rubenstein JL, Hsi ED, Johnson JL, Jung S-H, Nakashima MO, Grant B, et al. Intensive Chemotherapy and Immunotherapy in Patients With Newly Diagnosed Primary CNS Lymphoma: CALGB 50202 (Alliance 50202). 2013;31 25:3061\u20138; doi: \n                    https:\/\/doi.org\/10.1200\/jco.2012.46.9957\n                    \n                  .","journal-title":"Journal of Clinical Oncology"},{"key":"1511_CR14","doi-asserted-by":"publisher","unstructured":"Schaff LR, Grommes C. Updates on Primary Central Nervous System Lymphoma. Current oncology reports. 2018;20 2:11; doi: \n                    https:\/\/doi.org\/10.1007\/s11912-018-0666-1\n                    \n                  .","DOI":"10.1007\/s11912-018-0666-1"},{"key":"1511_CR15","doi-asserted-by":"publisher","first-page":"733","DOI":"10.2147\/NDT.S157959","volume":"14","author":"H Malikova","year":"2018","unstructured":"Malikova H, Burghardtova M, Koubska E, Mandys V, Kozak T, Weichet J. Secondary central nervous system lymphoma: spectrum of morphological MRI appearances. Neuropsychiatric Disease & Treatment. 2018;14:733\u201340.","journal-title":"Neuropsychiatric Disease & Treatment"},{"issue":"4","key":"1511_CR16","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1111\/j.1365-2141.2011.08928.x","volume":"156","author":"A Baraniskin","year":"2012","unstructured":"Baraniskin A, Deckert M, Schulte-Altedorneburg G, Schlegel U, Schroers R. Current strategies in the diagnosis of diffuse large B-cell lymphoma of the central nervous system. Br J Haematol. 2012;156(4):421\u201332. \n                    https:\/\/doi.org\/10.1111\/j.1365-2141.2011.08928.x\n                    \n                  .","journal-title":"Br J Haematol"},{"issue":"1","key":"1511_CR17","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3324\/haematol.2018.195834","volume":"104","author":"D Qualls","year":"2019","unstructured":"Qualls D, Abramson JS. Advances in risk assessment and prophylaxis for central nervous system relapse in diffuse large B-cell lymphoma. Haematologica. 2019;104(1):25\u201334. \n                    https:\/\/doi.org\/10.3324\/haematol.2018.195834\n                    \n                  .","journal-title":"Haematologica."},{"issue":"4","key":"1511_CR18","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1182\/blood.V91.4.1178","volume":"91","author":"K van Besien","year":"1998","unstructured":"van Besien K, Ha CS, Murphy S, McLaughlin P, Rodriguez A, Amin K, et al. Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma. Blood. 1998;91(4):1178\u201384.","journal-title":"Blood."},{"issue":"12","key":"1511_CR19","doi-asserted-by":"publisher","first-page":"2270","DOI":"10.3109\/10428194.2011.596966","volume":"52","author":"D Chihara","year":"2011","unstructured":"Chihara D, Oki Y, Matsuo K, Onoda H, Taji H, Yamamoto K, et al. Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: analyses with competing risk regression model. Leukemia & lymphoma. 2011;52(12):2270\u20135. \n                    https:\/\/doi.org\/10.3109\/10428194.2011.596966\n                    \n                  .","journal-title":"Leukemia & lymphoma."},{"issue":"3","key":"1511_CR20","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.blre.2011.12.001","volume":"26","author":"T Siegal","year":"2012","unstructured":"Siegal T, Goldschmidt N. CNS prophylaxis in diffuse large B-cell lymphoma: if, when, how and for whom? Blood Rev. 2012;26(3):97\u2013106. \n                    https:\/\/doi.org\/10.1016\/j.blre.2011.12.001\n                    \n                  .","journal-title":"Blood Rev"},{"key":"1511_CR21","doi-asserted-by":"publisher","first-page":"733","DOI":"10.2147\/ndt.s157959","volume":"14","author":"H Malikova","year":"2018","unstructured":"Malikova H, Burghardtova M, Koubska E, Mandys V, Kozak T, Weichet J. Secondary central nervous system lymphoma: spectrum of morphological MRI appearances. Neuropsychiatr Dis Treat. 2018;14:733\u201340. \n                    https:\/\/doi.org\/10.2147\/ndt.s157959\n                    \n                  .","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"5","key":"1511_CR22","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1093\/annonc\/mdp432","volume":"21","author":"D. Villa","year":"2009","unstructured":"Villa D, ., Connors JM, Shenkier TN, Gascoyne RD, Sehn LH, Savage KJ. Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: the impact of the addition of rituximab to CHOP chemotherapy. Annals of Oncology Official Journal of the European Society for Medical Oncology. 2010;21 5:1046.","journal-title":"Annals of Oncology"},{"issue":"17","key":"1511_CR23","doi-asserted-by":"publisher","first-page":"3896","DOI":"10.1182\/blood-2008-10-182253","volume":"113","author":"B Volkmar","year":"2009","unstructured":"Volkmar B, Norbert S, Samira Z, Markus L, Michael P. CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German high-grade non-Hodgkin lymphoma study group (DSHNHL). Blood. 2009;113(17):3896\u2013902.","journal-title":"Blood."},{"issue":"2","key":"1511_CR24","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.ejrad.2010.01.017","volume":"79","author":"E Senocak","year":"2011","unstructured":"Senocak E, Oguz KK, Ozgen B, Mut M, Ayhan S, Berker M, et al. Parenchymal lymphoma of the brain on initial MR imaging: a comparative study between primary and secondary brain lymphoma. Eur J Radiol. 2011;79(2):288\u201394. \n                    https:\/\/doi.org\/10.1016\/j.ejrad.2010.01.017\n                    \n                  .","journal-title":"Eur J Radiol"},{"issue":"3","key":"1511_CR25","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1093\/neuonc\/now238","volume":"19","author":"E Tabouret","year":"2017","unstructured":"Tabouret E, Houillier C, Martin-Duverneuil N, Blonski M, Soussain C, Ghesquieres H, et al. Patterns of response and relapse in primary CNS lymphomas after first-line chemotherapy: imaging analysis of the ANOCEF-GOELAMS prospective randomized trial. Neuro-oncology. 2017;19(3):422\u20139. \n                    https:\/\/doi.org\/10.1093\/neuonc\/now238\n                    \n                  .","journal-title":"Neuro-oncology."},{"key":"1511_CR26","unstructured":"Koubska E, Weichet J, Malikova H. Central nervous system lymphoma: a morphological MRI study. Neuro endocrinology letters. 2016;37 4:318."}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-019-1511-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12883-019-1511-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-019-1511-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,2]],"date-time":"2020-11-02T19:21:07Z","timestamp":1604344867000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-019-1511-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,4]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1511"],"URL":"https:\/\/doi.org\/10.1186\/s12883-019-1511-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.2.11623\/v4","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.11623\/v3","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.11623\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.11623\/v1","asserted-by":"object"}]},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,4]]},"assertion":[{"value":"28 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethical approval was provided by Beijing Tiantan Hospital Ethics Committee, Capital medical university (Ethical approval reference number: KYSB2016\u2013170). Informed consent was written obtained when patients were admitted to Department of Neurosurgery or Department of Hematology before initiation of chemotherapy.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"268"}}